When Sarah started her GLP-1 medication for weight loss, she was thrilled to see the numbers on the scale drop
With the PatSnap Eureka AI Agent , experts can explore how methylene blue is being repurposed, track IP filings, evaluate clinical data, and analyze competitive landscapes across geographies and therapeutic areas
But, the truth behind these products is often not what ads say
This is especially true for adults over 40, women going through menopause, and seniors working on strength, balance, and longevity
1,4 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified
Although these findings provide significant mechanistic insight, they primarily originated from animal or in vitro studies, and their translational relevance to long-term human health remains uncertain
